HUBUC Launches P1, a global card issuing and processing engine, becoming a Mastercard Network Enablement Partner
15.2.2023 10:07:00 EET | Business Wire | Press release
Leading fintech company HUBUC announces the immediate availability of its revolutionary issuing processor, a Mastercard-certified platform that makes card issuing easier than ever.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230213005527/en/
HUBUC Founders, Ignacio Javierre and Hasan Nawaz (Photo: Business Wire)
The platform has global scalability and plug-and-play connectivity at its core, allowing financial institutions and fintechs to enhance their customer experiences and deploy disruptive payment card use cases in a matter of weeks.
HUBUC decided to build P1, a new issuing processor in-house when existing ones proved to be running on legacy technology from the 1960's and provided outdated functionalities.
HUBUC's commitment with P1 is to bring lightning-fast performance, lean implementation and microservices architecture that allows scalability and innovation for years to come.
The cloud-based platform has key capabilities such as card-level spending controls, regulatory issuer reporting, cloud processing for scalability and comes with a stellar developer experience with Public Sandbox and OpenAPI specification.
Additionally, the platform offers strong customer authentication for enhanced security against fraud, and is GDPR, PSD2 and PCI DSS 3.2 Level 1 compliant.
The platform’s powerful issuing processor is the ultimate infrastructure to innovate with a Mastercard product and generate new revenue streams, improve unit economics and become a leading company in any sector.
P1 customers like Coverflex are an example of how to leverage HUBUC services. Coverflex’s solution allows a company to design more bespoke employee compensation, such as health insurance, meal allowance, fringe benefits and discounts, by aggregating multiple providers. This year Coverflex recently raised €15 million Series A, to keep increasing their existing customer base of 3,600+ companies, including Santander, Natixis, OysterHR, Bolt, Emma, Revolut and Smartex.
In a statement, Coverflex CEO Miguel Amaro said: “At Coverflex, we are dedicated to providing cutting-edge employee benefits via a smart card to our clients in Europe. Our focus on increasing the unit economics and scalability of our card product has been a top priority, and we are thrilled to announce that our partnership with HUBUC has enabled us to achieve this goal. Working with industry leaders like Ignacio and Hasan has been a truly enlightening experience, allowing us to expand our knowledge and understanding of the payments world. This collaboration has allowed us to significantly enhance our proposition to our clients, delivering increased efficiency and a better user experience for our cardholders.”
HUBUC's leadership team has been innovating in the fintech industry for years and brings experience building financial infrastructure across Europe to scale it globally.
HUBUC is backed by some of the best venture capitalists and operators in the industry, such as Y Combinator, Jeffrey Katzenberg (Managing Partner at WndrCo, Former Chairman Walt Disney Studios and DreamWorks Animations), Runa Capital, Village Global, Eric Yuan (Zoom), John Lilly (Mozilla), Immad Akhund (Mercury), John Bautista (Orrick), Charles Delingpole (ComplyAdvantage) among others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230213005527/en/
Contact information
HUBUC Inc.
press@hubuc.com | Ignacio Javierre
https://www.hubuc.com/about-us
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom